A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer

A Du Bois, HJ Lück, W Meier… - Journal of the …, 2003 - academic.oup.com
Background: Despite considerable improvement in the treatment of advanced ovarian
cancer, the optimization of efficacy and tolerability remains an important issue. Therefore, we …

[PDF][PDF] Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer

…, G Sledge, J Carmichael, HJ Lück… - Journal of Clinical …, 2008 - academia.edu
Background Overall survival (OS) can be observed only after prolonged follow-up, and any
potential effect of first-line therapies on OS may be confounded by the effects of subsequent …

A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women

…, J Bischoff, E Brain, ÁG Zotano, HJ Lück… - Cancer treatment …, 2013 - Elsevier
Endocrine therapy is the corner stone treatment for postmenopausal women with hormone
receptor-positive metastatic breast cancer (MBC). Besides tamoxifen and many older agents, …

[HTML][HTML] Multicenter phase II study of oral capecitabine (Xeloda “) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

…, AE Schindler, S Mohrmann, M Kaufmann, HJ Lück - Annals of …, 2003 - Elsevier
Background Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine
carbamate with high activity in metastatic breast cancer. This multicenter phase II study was …

[HTML][HTML] Advanced epithelial ovarian cancer: 1998 consensus statements

…, PG Harper, G Horvath, SB Kaye, HJ Lück… - Annals of oncology, 1999 - Elsevier
Background During an international workshop held in September 1998, a group of specialists
in the field of ovarian cancer reached consensus on a number of issues with implications …

[PDF][PDF] Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer

…, G Sledge, J Carmichael, HJ Lück… - Journal of clinical …, 2008 - avesis.acibadem.edu.tr
Purpose Taxanes (paclitaxel or docetaxel) have been sequenced or combined with anthracyclines
(doxorubicin or epirubicin) for the first-line treatment of advanced breast cancer. This …

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of …

…, W Schröder, JF Geay, HJ Lück… - Journal of the …, 2006 - academic.oup.com
Background: The combination of carboplatin and paclitaxel is the standard of care for the
treatment of ovarian cancer, yet rates of recurrence and death remain high. We performed a …

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

…, KH Baumann, J Bischoff, N Harbeck, HJ Lück… - European journal of …, 2011 - Elsevier
BACKGROUND: Continuation of trastuzumab plus capecitabine (XH) showed a significantly
improved overall response rate and time to progression compared with capecitabine (X) …

[HTML][HTML] PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a …

…, F von Koch, U Conrad, W Fett, C Kurzeder, HJ Lück… - Annals of oncology, 2011 - Elsevier
Background Preoperative chemotherapy is a recommended treatment of both primary
operable and locally advanced breast cancer. Strategies to improve efficacy include the use of …

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus-opinion of a german team of …

…, W Janni, W Jonat, M Kiechle, U Köhler, HJ Lück… - Breast care, 2013 - karger.com
The International Consensus Conference on the treatment of primary breast cancer takes
place every two years in St. Gallen, Switzerland. The panel in St. Gallen is composed of …